Drug Trial Radar · NCT02564497
A Study to Compare the Pharmacokinetics of Belatacept Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Process C
Last checked: Nov 20, 2026Latest source record: Apr 17, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
491
Actual
Start
Oct 2, 2015
Primary completion
Jan 27, 2017
Study completion Jan 27, 2017
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Sep 30, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to compare the Pharmacokinetics (PK) of Process E belatacept relative to Process C belatacept in Healthy subjects
Conditions
- Renal Transplantation
Interventions
Process E BelataceptBiological
Process C BelataceptBiological
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time (INF) of Belatacept.Time frame: Day 1 to Day 71
- Maximum Observed Serum Concentration (Cmax) of BelataceptTime frame: Day 1 to Day 71
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PPD Development
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.